These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16741885)

  • 1. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.
    Lautenbach E; Fishman NO; Metlay JP; Mao X; Bilker WB; Tolomeo P; Nachamkin I
    J Infect Dis; 2006 Jul; 194(1):79-85. PubMed ID: 16741885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.
    Lautenbach E; Metlay JP; Mao X; Han X; Fishman NO; Bilker WB; Tolomeo P; Wheeler M; Nachamkin I
    Clin Infect Dis; 2010 Aug; 51(3):280-5. PubMed ID: 20597679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia.
    Uchida Y; Mochimaru T; Morokuma Y; Kiyosuke M; Fujise M; Eto F; Harada Y; Kadowaki M; Shimono N; Kang D
    Int J Antimicrob Agents; 2010 Apr; 35(4):387-91. PubMed ID: 20138480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
    Li Q; Bi X; Diao Y; Deng X
    Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.
    Usein CR; Tatu-Chiţoiu D; Nica M; Ciontea SA; Palade AM; Condei M; Damian M
    Roum Arch Microbiol Immunol; 2008; 67(1-2):23-9. PubMed ID: 19284163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
    Chenia HY; Pillay B; Pillay D
    J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
    Yokota S; Sato T; Okubo T; Ohkoshi Y; Okabayashi T; Kuwahara O; Tamura Y; Fujii N
    Chemotherapy; 2012; 58(1):52-9. PubMed ID: 22343392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
    Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
    Yasufuku T; Shigemura K; Shirakawa T; Nakano Y; Tanaka K; Arakawa S; Kinoshita S; Nishimura K; Kawabata M; Fujisawa M
    Scand J Infect Dis; 2011 Feb; 43(2):83-8. PubMed ID: 20942776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of outpatient fecal colonization due to Escherichia coli Isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from the hospital.
    Lautenbach E; Tolomeo P; Mao X; Fishman NO; Metlay JP; Bilker WB; Nachamkin I
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3939-43. PubMed ID: 16982789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.